Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vera P Krymskaya

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Cellular Signalling|June 5, 2003
Tumour suppressors hamartin and tuberin: intracellular signallingVera P Krymskaya
Proceedings of the American Thoracic Society|December 21, 2007
Smooth muscle-like cells in pulmonary lymphangioleiomyomatosisVera P Krymskaya
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 4, 2007
Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promiseVera P Krymskaya
Expert Opinion on Orphan Drugs|January 19, 2016
Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Vera P Krymskaya
Cell Cycle (Georgetown, Tex.)|January 30, 2009
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospectsVera P Krymskaya, Elena A Goncharova
Annual Review of Medicine|January 19, 2017
Lymphangioleiomyomatosis: A Monogenic Model of MalignancyVera P Krymskaya, Francis X McCormack
Journal of Cellular Biochemistry|June 2, 2007
Pulmonary lymphangioleiomyomatosis (LAM): progress and current challengesElena A Goncharova, Vera P Krymskaya
Current Topics in Developmental Biology|May 15, 2007
Phosphodiesterases regulate airway smooth muscle function in health and diseaseVera P Krymskaya, Reynold A Panettieri
Hormones & Cancer|November 28, 2012
Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Stephen R Hammes, Vera P Krymskaya
Chest|August 23, 2019
Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future DirectionsHeng-Jia Liu, Vera P Krymskaya, Elizabeth P Henske
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Cellular Signalling|June 5, 2003
Tumour suppressors hamartin and tuberin: intracellular signallingVera P Krymskaya
Proceedings of the American Thoracic Society|December 21, 2007
Smooth muscle-like cells in pulmonary lymphangioleiomyomatosisVera P Krymskaya
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 4, 2007
Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promiseVera P Krymskaya
Expert Opinion on Orphan Drugs|January 19, 2016
Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Vera P Krymskaya
Cell Cycle (Georgetown, Tex.)|January 30, 2009
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospectsVera P Krymskaya, Elena A Goncharova
Annual Review of Medicine|January 19, 2017
Lymphangioleiomyomatosis: A Monogenic Model of MalignancyVera P Krymskaya, Francis X McCormack
Journal of Cellular Biochemistry|June 2, 2007
Pulmonary lymphangioleiomyomatosis (LAM): progress and current challengesElena A Goncharova, Vera P Krymskaya
Current Topics in Developmental Biology|May 15, 2007
Phosphodiesterases regulate airway smooth muscle function in health and diseaseVera P Krymskaya, Reynold A Panettieri
Hormones & Cancer|November 28, 2012
Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Stephen R Hammes, Vera P Krymskaya
Chest|August 23, 2019
Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future DirectionsHeng-Jia Liu, Vera P Krymskaya, Elizabeth P Henske
Pageof 8